Standardised Critical Care Strategies Improve Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in an Indian Peritoneal Malignancy Centre

被引:0
作者
Deepa Chandramohan
Faheez Mohamed
Syam Vikram
Deepak Damodaran
Shafeek Shamsudeen
Faslu Rahman
John J. Alapatt
Gokul R. Krishnan
R Dayananda
Muhammed P. Shahid
Arun P. Das
Jinu Varghese
Aditi Bhatt
Dileep Damodaran
机构
[1] MVR Cancer Centre and Research Institute,Department of Critical Care
[2] Peritoneal Malignancy Institute,Department of Surgical Oncology
[3] Basingstoke and North Hampshire Hospital,Department of Surgical Oncology
[4] MVR Cancer Centre and Research Institute,undefined
[5] KD Hospital,undefined
来源
Indian Journal of Surgical Oncology | 2023年 / 14卷
关键词
Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Morbidity; Postoperative management protocol; Outcomes;
D O I
暂无
中图分类号
学科分类号
摘要
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major undertaking with profound peri-operative metabolic and haemodynamic alterations. It requires standardised protocols for immediate postoperative intensive care management to improve patient-related outcomes. A retrospective analysis of a prospectively maintained data-base of 244 patients who underwent CRS and HIPEC between June 2017 and July 2022 in our institute was done. Based on the audit, six strategies were implemented, namely, (1) dynamic multiparameter-based IVF therapy to aggressively correct the hyperlactatemia, (2) initiation of IV 20% human albumin infusion from POD-0, (3) correction of serum iCa2+ levels, (4) initiation of diuresis from POD-1, (5) prophylactic use of HFNO immediately post-extubation and (6) serum procalcitonin level-based empiric escalation of IV antibiotics. Patients were divided into two cohorts, pre-protocol group of 145 patients (from June 2017 to December 2020) and post-protocol group comprising of 99 patients (from January 2021 to July 2022), and were analysed for compliance and patient-related outcomes. Implementation of these strategies improved the patient-related outcomes among the two cohorts with significant reduction of Clavien-Dindo grade III/IV complications and improvement in failure to rescue (FTR) index (p < 0.05). There was highly significant reduction in median ICU and hospital stay among the two cohorts (p < 0.001). The formulated protocols of management strategies especially multiparameter-based dynamic fluid therapy, planned diuresis and prophylactic HFNO have improved the outcomes in our patients undergoing CRS and HIPEC.
引用
收藏
页码:920 / 927
页数:7
相关论文
共 101 条
  • [1] Clavien PA(2009)The Clavien-Dindo classification of surgical complications: five-year experience Ann Surg 250 187-196
  • [2] Barkun J(2019)Failure to rescue in surgical patients: a review for acute care surgeons J Trauma Acute Care Surg 87 699-706
  • [3] de Oliveira ML(2005)Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer Int Semin Surg Oncol 2 3-832
  • [4] Vauthey JN(2019)Perioperative fluid therapy for major surgery Anesthesiology 130 825-1946
  • [5] Dindo D(2018)High-flow nasal cannula in adults with acute respiratory failure and after extubation: a systematic review and meta-analysis Respir Res 19 202-29
  • [6] Schulick RD(2020)High-flow nasal cannula in the immediate postoperative period: a systematic review and meta-analysis Chest 158 1934-79
  • [7] Hatchimonji JS(2021)The utility of HACOR score in predicting failure of high-flow nasal oxygen in acute hypoxemic respiratory failure Adv Respir Med 89 23-803
  • [8] Kaufman EJ(2019)Failure-to-rescue following cytoreductive surgery with or without HIPEC is determined by the type of complication-a retrospective study by INDEPSO Indian J Surg Oncol 10 71-585
  • [9] Sharoky CE(2016)What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures J Surg Oncol 113 796-1279
  • [10] Ma L(2014)Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients J Am Coll Surg 218 573-239